Clinical Trials Browser

Withdrawn × INDUSTRY × Classical hematology × Clear all

NCT06254742 2025-08-07

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

NCT05927012 2023-11-24

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Phase 2 Withdrawn

Classical hematologyMyeloid

Myelodysplastic Syndromes, Anemia, Iron-Deficiency, Primary Myelofibrosis

NCT05261646 2023-09-28

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Phase 3 Withdrawn

Classical hematology

Chemotherapy-Induced Thrombocytopenia

NCT05061654 2023-08-14

CEF-10

Phase 4 Withdrawn

Classical hematologyOther hematologic neoplasm

Hematologic Neoplasms, Febrile Neutropenia

NCT03087370 2018-12-07

A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome

Withdrawn

Classical hematology

WHIM syndrome, Primary Immunodeficiency Diseases, Agammaglobulinemia, Herpes Simplex, Infections, Neutropenia, Warts

NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Phase 2 Withdrawn

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01206907 2012-08-17

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Phase 3 Withdrawn

Classical hematology

Anemia, Sickle Cell, Arthritis, Juvenile, Neoplasms, Chronic Pain